Department of Interventional Radiology, The First Medical Center of PLA General Hospital, Beijing 100853, China.
Department of Radiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Dig Liver Dis. 2023 Jul;55(7):899-906. doi: 10.1016/j.dld.2022.12.025. Epub 2023 Jan 19.
To evaluate the safety and the long-term outcomes of transarterial embolization (TAE) with lipiodol-bleomycin emulsion (LBE) plus N-Butyl cyanoacrylate (NBCA) in the treatment of children with large symptomatic focal nodular hyperplasia (FNH).
This is a retrospective case serial study. Children (aged <18 years) with FNH were treated. Indications for TAE were patients who were presenting with FNH related abdominal pain and the maximum diameter of FNH is more than 7 cm, and who were not candidates for surgical treatment. Technical success, adverse events, symptoms relief rate, and changes in the lesion size after TAE were evaluated.
Between January 2003 and February 2018, 17 pediatric patients were included. Technical success was achieved in all patients. Mean follow-up was 67.5 months. All patients had complete resolution of abdominal symptom. The mean largest diameter of the lesions decreased from 10.5 cm to 1.9 cm (P < 0.01). The mean volume reduction rate was 96.9%. The complete resolution of the FNH was observed in 16 patients. No further therapy was needed for all patients.
TAE with LBE plus NBCA appears to be a safe and effective treatment in pediatric patients with large symptomatic FNH. It could be considered as the first-line treatment for symptomatic large FNH.
评估经动脉栓塞术（TAE）联合碘油-平阳霉素乳剂（LBE）加 n-丁基氰丙烯酸酯（NBCA）治疗儿童大症状性局灶性结节性增生（FNH）的安全性和长期疗效。
这是一项回顾性病例系列研究。对 FNH 患儿进行治疗。TAE 的适应证为因 FNH 相关腹痛就诊且 FNH 的最大直径大于 7cm，且不适合手术治疗的患者。评估 TAE 的技术成功率、不良事件、症状缓解率以及栓塞后病变大小的变化。
2003 年 1 月至 2018 年 2 月期间，共纳入 17 例儿科患者。所有患者均获得技术成功。中位随访时间为 67.5 个月。所有患者的腹部症状均完全缓解。病变的最大直径从 10.5cm 缩小至 1.9cm（P<0.01），平均体积缩小率为 96.9%。16 例患者的 FNH 完全消退。所有患者均无需进一步治疗。
LBE 联合 NBCA 的 TAE 治疗儿童大症状性 FNH 安全有效。对于有症状的大 FNH，可考虑作为一线治疗方法。
